Pharmacyclics, Inc.
PCYCNext catalyst
Ibrutinib
Diffuse Large B Cell Lymphoma Relapsed
Get an email about PCYC's next catalysts
Track Pharmacyclics (PCYC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline
3 upcoming, 0 past
Ibrutinib Phase 3 Est. Readout (CAN3001)
Estimated primary completion for Ibrutinib trial (NCT01804686) in Chronic Lymphocytic Leukemia. Topline data typically follows completion by weeks to months.
SourceIbrutinib Phase 3 Est. Readout
Estimated primary completion for Ibrutinib trial (NCT04212013) in Marginal Zone Lymphoma. Topline data typically follows completion by weeks to months.
SourceIbrutinib Phase 2 Est. Readout
Estimated primary completion for Ibrutinib trial (NCT04450173) in Ann Arbor Stage II Follicular Lymphoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Motexafin Gadolinium
Brain Neoplasms
PCI-32765 (Ibrutinib)
Lymphoma
MGd
Metastatic Cancer
Ibrutinib (as Subsequent Therapy)
Leukemia, Lymphocytic, Chronic, B-Cell
Prednisone (or equivalent)
Lymphoma
Ibrutinib Oral Capsule
Follicular Lymphoma
Next-line ibrutinib
Chronic Lymphocytic Leukemia
Ibrutinib
Diffuse Large B Cell Lymphoma Relapsed
ofatumumab
B-cell Chronic Lymphocytic Leukemia
Chlorambucil
Chronic Lymphocytic Leukemia
Fludarabine
Chronic Lymphocytic Leukemia
HD- Methotrexate (MTX)
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)
Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
B-cell Chronic Lymphocytic Leukemia
Rituximab + HD- Methotrexate (MTX)
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)
procarbazine
Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)
DA-EPOCH-R
Diffuse Large B Cell Lymphoma Relapsed
Pneumococcal 13-valent Conjugate Vaccine
Chronic Lymphocytic Leukemia
Trivalent Influenza Vaccine
Chronic Lymphocytic Leukemia
Cirmtuzumab plus Ibrutinib
B-cell Chronic Lymphocytic Leukemia
Cirmtuzumab (RDR) plus ibrutinib
B-cell Chronic Lymphocytic Leukemia
PCI-24781
Lymphoma
MEDI4736
Diffuse Large B-Cell Lymphoma
Motexafin Gadolinium Injection
Multiple Myeloma
PCI-27483
Pancreatic Cancer
PCI-32765
B-cell Chronic Lymphocytic Leukemia
GA101
Chronic Lymphocytic Leukemia
Blinatumomab
Adult B Acute Lymphoblastic Leukemia
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Chronic Lymphocytic Leukemia
GCSF
Sarcoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Motexafin Gadolinium | Phase 3 | Brain Neoplasms | - | - |
PCI-32765 (Ibrutinib) | Phase 3 | Lymphoma | - | - |
MGd | Phase 3 | Metastatic Cancer | - | - |
Ibrutinib (as Subsequent Therapy) | Phase 3 | Leukemia, Lymphocytic, Chronic, B-Cell | - | - |
Prednisone (or equivalent) | Phase 3 | Lymphoma | - | - |
Ibrutinib Oral Capsule | Phase 3 | Follicular Lymphoma | - | - |
Next-line ibrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Ibrutinib | Phase 3 | Diffuse Large B Cell Lymphoma Relapsed | - | - |
ofatumumab | Phase 3 | B-cell Chronic Lymphocytic Leukemia | - | - |
Chlorambucil | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Fludarabine | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
HD- Methotrexate (MTX) | Phase 2 | Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | - | - |
Cirmtuzumab (2-16 kg/mg) plus Ibrutinib | Phase 2 | B-cell Chronic Lymphocytic Leukemia | - | - |
Rituximab + HD- Methotrexate (MTX) | Phase 2 | Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | - | - |
procarbazine | Phase 2 | Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | - | - |
DA-EPOCH-R | Phase 2 | Diffuse Large B Cell Lymphoma Relapsed | - | - |
Pneumococcal 13-valent Conjugate Vaccine | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Trivalent Influenza Vaccine | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Cirmtuzumab plus Ibrutinib | Phase 2 | B-cell Chronic Lymphocytic Leukemia | - | - |
Cirmtuzumab (RDR) plus ibrutinib | Phase 2 | B-cell Chronic Lymphocytic Leukemia | - | - |
PCI-24781 | Phase 2 | Lymphoma | - | - |
MEDI4736 | Phase 2 | Diffuse Large B-Cell Lymphoma | - | - |
Motexafin Gadolinium Injection | Phase 2 | Multiple Myeloma | - | - |
PCI-27483 | Phase 2 | Pancreatic Cancer | - | - |
PCI-32765 | Phase 2 | B-cell Chronic Lymphocytic Leukemia | - | - |
GA101 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Blinatumomab | Phase 2 | Adult B Acute Lymphoblastic Leukemia | - | - |
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
GCSF | Phase 2 | Sarcoma | - | - |
Frequently asked questions
What is in Pharmacyclics, Inc.'s drug pipeline?→
CatalystAlert tracks 29 drug candidates in Pharmacyclics, Inc.'s (PCYC) pipeline across Phase 3, Phase 2. Its lead program is Ibrutinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Pharmacyclics, Inc.'s next FDA catalyst?→
Pharmacyclics, Inc.'s (PCYC) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PCYC biotech catalysts?→
Add PCYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharmacyclics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
